Regentis Biomaterials opened at $1.27, in line with its previous close of $1.27. In the last trading session, the stock traded between $1.18 and $1.27. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Regentis Biomaterials is now worth
$ 16.48
Resulting in a loss of
$ 83.52 (83.52%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.03 (-2.68%)
Day High
$1.27
Day Low
$1.18
Day Open
$1.27
Prev Close
$1.27
Volume
22,950
1W Return
-7.83%
1M Return
-24.17%
3M Return
-33.55%
6M Return
-43.20%
1Y Return
-83.52%
Fundamentals
Market Cap ($ Mn)
9
PE Ratio
-
PB Ratio
2.18
PEG Ratio
-
ROE
-
ROCE
380.83%
EPS (TTM)
-
Investment Returns
1 Week
-7.83%
1 Month
-24.17%
3 Months
-33.55%
6 Months
-43.20%
9 Months
-73.70%
Financials
Quarterly
All values in $ Mn
No data available.
Updates
11Sep
Regentis Biomaterials H1 Results: EPS loss narrows 62% YoY
Regentis Biomaterials reported an H1 EPS of $(0.44). Losses narrowed by 62.39% compared to $(1.17) EPS in H1 last year. No revenue or margin data was disclosed in the source.
2mo ago
20Jul
Regentis secures Japan patent for solvent-free GelrinC process
Regentis Biomaterials Ltd. secured a Notice of Allowance from the Japan Patent Office for its organic solvent-free GelrinC manufacturing process and ready-to-use liquid formulation. This strengthens IP in a key market as the firm advances European commercialization and US trials. The solvent-free process boosts yield by 400% and enhances safety.
3mo ago
17Jun
Regentis Biomaterials stock rises on offering withdrawal
Regentis Biomaterials Ltd. shares gained 11.16% to $6.87 on Wednesday after withdrawing its proposed $10 million public offering of 3.33 million shares. The company filed to withdraw its Form F-1 registration statement effective June 15, eliminating potential equity dilution. Additionally, management announced plans to initiate European surgeon training for its GelrinC product in Q3 2026 to drive commercialization.
